Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy

NMR in Biomedicine

Volumn 23, Issue 9, 2010, Pages 1017-1026

  Testa, Claudia ^a   Schiavina, Riccardo ^a   Lodi, Raffaele ^a   Salizzoni, Eugenio ^a   Tonon, Caterina ^a   D'Errico, Antonietta ^a   Corti, Barbara ^a   Morselli Labate, Antonio Maria ^a   Franceschelli, Alessandro ^a   Bertaccini, Alessandro ^a   Manferrarik, Fabio ^a   Grigioni, Walter Francesco ^a   Canini, Romeo ^a   Martorana, Giuseppe ^a   Barbiroli, Bruno ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Magnetic resonance imaging; Magnetic resonance spectroscopic imaging; Prostate cancer; Transrectal ultrasound biopsy

Indexed keywords

AREA UNDER THE ROC CURVE; BENIGN PROSTATIC HYPERPLASIA; CUT-OFF; DESCRIPTIVE STATISTICS; DETECTION RATES; FALSE POSITIVE; HISTOPATHOLOGICAL ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; MEAN AGES; PROSTATE CANCERS; PROSTATE GLANDS; REGION ANALYSIS; ROC ANALYSIS; TRANSITION ZONES; TRANSRECTAL ULTRASOUND;

DISEASES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; RATING; RESONANCE; ULTRASONIC APPLICATIONS; ULTRASONICS;

BIOPSY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TRANSRECTAL ULTRASOUND BIOPSY;

AREA UNDER CURVE; BIOPSY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATITIS; SENSITIVITY AND SPECIFICITY;

EID: 79251481861     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1522     Document Type: Article

References (42)

1. Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can. J. Urol. 2005; 12: 44-48.
2. Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC. Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol. Oncology. 2004; 22: 7-10.
3. Heijmink SW, Barentsz JO. Contrast-enhanced versus systematic transrectal ultrasound-guided prostate cancer detection: an overview of techniques and a systematic review. Eur. J. Radiol. 2007; 63(3): 310-316.
4. Loch T. Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies. World J/Urol. 2007; 25(4): 375-380.
5. Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, Corvin S, Sievert K-D, Claussen CD, Stenzl A, Schlemmer H-P. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur. Urol. 2006; 50(4): 738-748; discussion 748-749.
6. Hambrok T, Futterer JJ, Huisman HJ, Hulsergen-vandeKaa C, van Basten JP, van Oort I, Witjes JA, Barentsz JO. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest. Radiol. 2008; 43(10): 686-694.
7. Pondman KM, Fütterer JJ, ten Haken, Schultze B, Kool LJ, Witjes JA, Hambrock T, Macura KJ, Barentsz JO. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur. Urology. 2008; 54: 517-527.
8. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999; 213: 473-480.
9. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J. Urol. 2000; 164: 400-404.
10. Kumar V, Jagannathan NR, Kumar R, Thulkar S, Gupta SD, Hemal AK, Gupta N. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10ng/ml. NMR Biomed. 2007; 20(1): 11-20.
11. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology. 2005; 236(3): 903-910.
12. Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debré B, Zerbib M. Negative prostatic biopsies in patients with high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur. Urol. 2005; 47: 582-586.
13. Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, Scardino PT, Hricak H. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006; 239(3): 784-792.
14. Zakian KL, Eberhardt S, Hricak H, Shula-Dave A, Kleinman S, Muruganandham M, Sircar K, Kattan MW, Reuter VE, Scardino PT, Koucher JA. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology. 2003; 229(1): 241-247.
15. 3) spatial resolution. Radiology. 1996; 198; 795-805.
16. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology. 1997; 202: 697-702.
17. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann. NY Acad. Sci. 1987; 508: 333-348.
18. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn. Reson. Med. 1997; 38: 311-321.
19. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn. Reson. Med. 2000; 43: 23-33.
20. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging. 2002; 16: 451-463.
21. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J. Prostate Depiction at Endorectal MR Spectroscopic Imaging: Investigation of a Standardized Evaluation System. Radiology. 2004; 233: 701-708.
22. Pezzilli R, Billi P, Miniero R, Fiocchi M, Cappelletti O, Morselli-Labate AM, Barakat B, Sprovieri G, Miglioli M. Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Dig. Dis. Sci. 1995; 40(11): 2341-2348.
23. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: who, how and when? A review. Eur. Urol. 2002; 42: 93-103.
24. Djavan B, Zlotta AR, Ekane S, Remzi M, Kramer G, Roumequere T, Etemad M, Wolfram R, Schulman CC, Marberger M. Is onset of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volume on prostate cancer yield. Eur. Urol. 2000; 38: 218-224.
25. 11C-Choline PET/CT. Radiology. 2007; 244(3): 797-806.
26. Raja J, Ramachandran N, Munneke G, Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin. Radiol. 2006; 61(2): 142-153.
27. Hricak H, Eberhardt SC, Olgac S, Muruganandham M, Scardino PT, Reuter VE, Koutcher JA, Zakian KL. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology. 2004; 231: 717-724.
28. Casciani E, Pollettini E, Bertini L, Pansadoro V, Gualdi GF. Granulomatous prostatitis: A pitfall in endorectal MR imaging and 3D MR spectroscopic imaging. Eur. J. Radiol. Extra. 2005; 54: 111-114.
29. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50: 944-954.
30. Swindle P, Ramadan S, Stanwell P, McCredie S, Russell P, Mountford C. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. MAGMA. 2008; 21(6): 423-434.
31. Prando A, Billis A. Focal prostatic atrophy: mimicry of prostatic cancer on TRUS and 3D-MRSI studies. Abdom. Imaging. 2009; 34: 271-275.
32. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen ACA, schmitt LD, Carroll PR, Kurhanewicz J. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience. Radiology. 2007; 242(2): 483-489.
33. McNeal J, Noldus J. Limitations of transition zone needle biopsy findings in the prediction of transition zone cancer and tissue composition of benign nodular hyperplasia. Urology. 1996; 48: 751-756.
34. Li H, Sugimura K, Kaji Y, Kitamura Y, Fujii M, Hara I, Tachibana M. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am. J. Roentgenol. 2006; 186: 729-742.
35. Swanson MG, Zektzer AS, Tabatabai ZL, simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. Quantitative analysis of prostate metabolites using 1H HR-MAS Spectroscopy. Magn. Res. Med. 2006; 55: 1257-1264.
36. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J. Magn. Reson. Imaging. 2002; 16: 196-200.
37. Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Trachtenberg J. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am. J. Roentgenol. 2007; 189: 323-328.
38. Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T, Yamamoto A, Tanimoto D, Ito K. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J. Magn. Reson. Imaging. 2008; 28(3): 720-726.
39. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiologica. 2008; 49(10): 1207-1213.
40. Lemaitre L, Puech P, Poncelet E, Bouyé S, Leroy X, Biserte J, Villers A. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur. Radiol. 2009; 19(2): 470-480.
41. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr. Opin. Urol. 2008; 18: 71-77.
42. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, Cho H, Kawashima A, Tempany-Afdhal CM, Macura KJ, Rosen M, Gerst SR, Kurhanewicz J. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009; 251(1): 122-133.